CRSPCRISPR Therapeutics AG
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+20% of shares).
Choppy, but holding above its 200-day average. Price is +0% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How CRSP is trading
CRISPR Therapeutics AG is −14% over the past year while the S&P 500 is +18%: 33 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +0.21%
vs 200-day average · close to trend
- RSI (14)
- 38
RSI (14) · neutral
- Below its 52-week high
- 30%
Below its 52-week high
Details›
- Last close2026-10-09
- $53.41
- 1 monthS&P 500 +2.7%
- +2.2%
- 1 yearS&P 500 +18%
- −14%
- 5 yearsS&P 500 +88%
- −54%
- vs 50-day average$54.72
- −2.4%
- 52-week high
- $76.78
- 52-week low
- $44.34
- Annualised volatility
- 60%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$992K
| Year | Return |
|---|---|
| 2026 (year to date) | +1.8% |
| 2025 | +33% |
| 2024 | −37% |
| 2023 | +54% |
| 2022 | −46% |
| 2021 | −51% |
| 2020 | +151% |
| 2019 | +113% |
| 2018 | +22% |
| 2017 | +16% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 6 of 10 | +7.3% |
| Feb | 10 | 7 of 10 | +9.8% |
| Mar | 10 | 2 of 10 | −11% |
| Apr | 10 | 7 of 10 | +0.56% |
| May | 10 | 6 of 10 | +8.7% |
| Jun | 10 | 7 of 10 | +11% |
| Jul | 10 | 7 of 10 | +2.4% |
| Aug | 10 | 5 of 10 | +0.88% |
| Sep | 10 | 2 of 10 | −5.5% |
| Oct | 10 | 3 of 10 | −4.4% |
| Nov | 10 | 7 of 10 | +17% |
| Dec | 10 | 2 of 10 | −6.5% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry